Status:
COMPLETED
Serum Level of Lipopolysaccharide-binding Protein (LBP) and Atherosclerosis in Hemodialysis Patients
Lead Sponsor:
Tungs' Taichung Metroharbour Hospital
Conditions:
Systemic Inflammatory Response Syndrome
Eligibility:
All Genders
20-90 years
Brief Summary
Background In hemodialysis (HD) patients, impaired gut barrier and alteration in microbiota in the gut is thought to increase the risk of bacterial translocation and chronic inflammation. Lipopolysacc...
Detailed Description
Study Design and Population Patient Population To be included in the study, patients have to be at least 20-years-old and on outpatient hemodialysis (HD) for at least 3 months. Patients are excluded...
Eligibility Criteria
Inclusion
- Both sexes aged between 20-90 years.
- Received stable hemodialysis at least 3 months.
- Written informed consent.
Exclusion
- patients with severe infections, severe heart disease and liver disease, malignancy, autoimmune disorders, severe malnutrition, or clinical conditions requiring oral nutrition supplements;
- Inability to follow protocol.
- Pregnancy or wishing/trying to get pregnant
Key Trial Info
Start Date :
June 3 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2021
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT03427307
Start Date
June 3 2018
End Date
January 31 2021
Last Update
June 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tungs' Taichung MetroHarbour Hospital
Taichung, Taiwan